Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 15, 2025

MIPE

RRID:SCR_003065

Type: Tool

Proper Citation

MIPE (RRID:SCR_003065)

Resource Information

URL: http://sourceforge.net/projects/mipe/

Proper Citation: MIPE (RRID:SCR_003065)

Description: A XML format that enables genomics researchers to store critical information on PCR experiments. Accompagnying perl scripts are written to read from (dbSTS) or write to a MIPE XML file.

Synonyms: Minimal Information for PCR Experiments

Resource Type: interchange format, standard specification, data or information resource, software resource, narrative resource

Keywords: standalone software, pcr, xml, data storage, data exchange

Funding:

Resource Name: MIPE

Resource ID: SCR 003065

Alternate IDs: OMICS_02358

Alternate URLs: http://mipe.sourceforge.net/, https://sources.debian.org/src/mipe/

Record Creation Time: 20220129T080217+0000

Record Last Update: 20250412T054757+0000

Ratings and Alerts

No rating or validation information has been found for MIPE.

No alerts have been found for MIPE.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Arakawa Y, et al. (2024) Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts. Cancer research communications, 4(3), 834.

Zhang Y, et al. (2024) O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer. Nature communications, 15(1), 5597.

Ceribelli M, et al. (2024) Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity. Proceedings of the National Academy of Sciences of the United States of America, 121(49), e2413372121.

Flickinger KM, et al. (2024) Conditional lethality profiling reveals anticancer mechanisms of action and drug-nutrient interactions. Science advances, 10(40), eadq3591.

Evsen L, et al. (2023) Comparative Assessment and High-Throughput Drug-Combination Profiling of TEAD-Palmitoylation Inhibitors in Hippo Pathway Deficient Mesothelioma. Pharmaceuticals (Basel, Switzerland), 16(12).

Kumari A, et al. (2023) mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer. JCI insight, 8(5).

Cheff DM, et al. (2023) Development of an assay pipeline for the discovery of novel small molecule inhibitors of human glutathione peroxidases GPX1 and GPX4. Redox biology, 63, 102719.

Kasprzak MM, et al. (2023) Replacement of milk fat by rapeseed oil stabilised emulsion in commercial yogurt. PeerJ, 11, e16441.

Zhu W, et al. (2023) O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer. Research square.

Arang N, et al. (2023) High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma. Cell

reports. Medicine, 4(11), 101244.

Yang Y, et al. (2022) Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma. Nature communications, 13(1), 5469.

Chang LS, et al. (2021) Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PloS one, 16(7), e0252048.

Thomas A, et al. (2021) Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. Cancer cell, 39(4), 566.

Gandelman M, et al. (2021) The AKT modulator A-443654 reduces ?-synuclein expression and normalizes ER stress and autophagy. The Journal of biological chemistry, 297(4), 101191.

Terribas E, et al. (2020) KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. Neuro-oncology advances, 2(Suppl 1), i62.

Wei D, et al. (2020) Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments. Genes, chromosomes & cancer, 59(8), 472.

Cubitt B, et al. (2020) A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. Antiviral research, 173, 104667.

Asawa RR, et al. (2020) A high-throughput screening platform for Polycystic Kidney Disease (PKD) drug repurposing utilizing murine and human ADPKD cells. Scientific reports, 10(1), 4203.

Zhu W, et al. (2020) Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening. bioRxiv: the preprint server for biology.

Dextras C, et al. (2020) Identification of Small Molecule Enhancers of Immunotherapy for Melanoma. Scientific reports, 10(1), 5688.